After six years as commissioner of the US FDA, The Washington Times reports that David Kessler intends to join the exodus of top-level officials from President Clinton's administration. Dr Kessler has been assiduous in efforts to have nicotine classified as a drug and thus made subject to regulation. He has also led attempts to speed the agency's approvals processes for drugs and devices. Dr Kessler's spokesman told Clinica that the commissioner's departure was not imminent, but that Dr Kessler had accomplished all his long term goals for the agency.
David Kessler likely to retire from the FDA:
After six years as commissioner of the US FDA, The Washington Times reports that David Kessler intends to join the exodus of top-level officials from President Clinton's administration. Dr Kessler has been assiduous in efforts to have nicotine classified as a drug and thus made subject to regulation. He has also led attempts to speed the agency's approvals processes for drugs and devices. Dr Kessler's spokesman told Clinica that the commissioner's departure was not imminent, but that Dr Kessler had accomplished all his long term goals for the agency.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
• By
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
• By
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
• By
While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.
• By
GE HealthCare anticipates most of the $0.85 EPS tariff impact will play out in the second half of 2025. Jay Saccaro, vice president and CFO, said the tariff-related burden is minimal in Q1 at about $10 million, rising to nearly $100 million in Q2 and then spiking to around $200 million each in Q3 and Q4.
• By
Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.